Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMPART adjuvant trial in resected renal cell carcinoma
ISRCTN53348826Phase 3Active, not recruiting
- Sponsor
- University College London
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in renal cell carcinoma (RCC) (3 arms), sponsored by University College London. Started Oct 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN53348826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53348826.